Dopamine D4 receptors may alleviate antipsychotic-induced parkinsonism.
Identifieur interne : 001786 ( PubMed/Curation ); précédent : 001785; suivant : 001787Dopamine D4 receptors may alleviate antipsychotic-induced parkinsonism.
Auteurs : P. Seeman [Canada] ; R. Corbett ; H H Van TolSource :
- Advances in pharmacology (San Diego, Calif.) [ 1054-3589 ] ; 1998.
English descriptors
- KwdEn :
- Antipsychotic Agents (adverse effects), Clozapine (metabolism), Dopamine (metabolism), Dopamine D2 Receptor Antagonists, Humans, Muscarinic Antagonists, Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (prevention & control), Radioligand Assay, Receptor, Serotonin, 5-HT2A, Receptors, Dopamine D2 (metabolism), Receptors, Dopamine D4, Receptors, Muscarinic (metabolism), Receptors, Serotonin (metabolism), Serotonin Antagonists.
- MESH :
- chemical , adverse effects : Antipsychotic Agents.
- chemical , metabolism : Clozapine, Dopamine, Receptors, Dopamine D2, Receptors, Muscarinic, Receptors, Serotonin.
- chemical : Dopamine D2 Receptor Antagonists, Muscarinic Antagonists, Receptor, Serotonin, 5-HT2A, Receptors, Dopamine D4, Serotonin Antagonists.
- chemically induced : Parkinson Disease, Secondary.
- prevention & control : Parkinson Disease, Secondary.
- Humans, Radioligand Assay.
PubMed: 9327943
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001786
Links to Exploration step
pubmed:9327943Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine D4 receptors may alleviate antipsychotic-induced parkinsonism.</title><author><name sortKey="Seeman, P" sort="Seeman, P" uniqKey="Seeman P" first="P" last="Seeman">P. Seeman</name><affiliation wicri:level="1"><nlm:affiliation>Pharmacology Department, University of Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Pharmacology Department, University of Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Corbett, R" sort="Corbett, R" uniqKey="Corbett R" first="R" last="Corbett">R. Corbett</name></author><author><name sortKey="Van Tol, H H" sort="Van Tol, H H" uniqKey="Van Tol H" first="H H" last="Van Tol">H H Van Tol</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9327943</idno><idno type="pmid">9327943</idno><idno type="wicri:Area/PubMed/Corpus">001786</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001786</idno><idno type="wicri:Area/PubMed/Curation">001786</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001786</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dopamine D4 receptors may alleviate antipsychotic-induced parkinsonism.</title><author><name sortKey="Seeman, P" sort="Seeman, P" uniqKey="Seeman P" first="P" last="Seeman">P. Seeman</name><affiliation wicri:level="1"><nlm:affiliation>Pharmacology Department, University of Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Pharmacology Department, University of Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Corbett, R" sort="Corbett, R" uniqKey="Corbett R" first="R" last="Corbett">R. Corbett</name></author><author><name sortKey="Van Tol, H H" sort="Van Tol, H H" uniqKey="Van Tol H" first="H H" last="Van Tol">H H Van Tol</name></author></analytic><series><title level="j">Advances in pharmacology (San Diego, Calif.)</title><idno type="ISSN">1054-3589</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antipsychotic Agents (adverse effects)</term><term>Clozapine (metabolism)</term><term>Dopamine (metabolism)</term><term>Dopamine D2 Receptor Antagonists</term><term>Humans</term><term>Muscarinic Antagonists</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (prevention & control)</term><term>Radioligand Assay</term><term>Receptor, Serotonin, 5-HT2A</term><term>Receptors, Dopamine D2 (metabolism)</term><term>Receptors, Dopamine D4</term><term>Receptors, Muscarinic (metabolism)</term><term>Receptors, Serotonin (metabolism)</term><term>Serotonin Antagonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Clozapine</term><term>Dopamine</term><term>Receptors, Dopamine D2</term><term>Receptors, Muscarinic</term><term>Receptors, Serotonin</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Dopamine D2 Receptor Antagonists</term><term>Muscarinic Antagonists</term><term>Receptor, Serotonin, 5-HT2A</term><term>Receptors, Dopamine D4</term><term>Serotonin Antagonists</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Radioligand Assay</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9327943</PMID><DateCreated><Year>1997</Year><Month>11</Month><Day>25</Day></DateCreated><DateCompleted><Year>1997</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1054-3589</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><PubDate><Year>1998</Year></PubDate></JournalIssue><Title>Advances in pharmacology (San Diego, Calif.)</Title><ISOAbbreviation>Adv. Pharmacol.</ISOAbbreviation></Journal><ArticleTitle>Dopamine D4 receptors may alleviate antipsychotic-induced parkinsonism.</ArticleTitle><Pagination><MedlinePgn>478-82</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seeman</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pharmacology Department, University of Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corbett</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Van Tol</LastName><ForeName>H H</ForeName><Initials>HH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Pharmacol</MedlineTA><NlmUniqueID>9015397</NlmUniqueID><ISSNLinking>1054-3589</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493599">DRD4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065127">Dopamine D2 Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018727">Muscarinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012702">Serotonin Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>137750-34-6</RegistryNumber><NameOfSubstance UI="D050638">Receptors, Dopamine D4</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065127" MajorTopicYN="N">Dopamine D2 Receptor Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018727" MajorTopicYN="N">Muscarinic Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044402" MajorTopicYN="N">Receptor, Serotonin, 5-HT2A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050638" MajorTopicYN="N">Receptors, Dopamine D4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011985" MajorTopicYN="N">Receptors, Serotonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012702" MajorTopicYN="N">Serotonin Antagonists</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>11</Month><Day>5</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>11</Month><Day>5</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9327943</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001786 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001786 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:9327943
|texte= Dopamine D4 receptors may alleviate antipsychotic-induced parkinsonism.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:9327943" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |